{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:11:21Z","timestamp":1761491481245},"reference-count":154,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2022,11,2]]},"DOI":"10.1080\/13543784.2022.2138742","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T20:20:31Z","timestamp":1666297231000},"page":"1169-1186","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Early stage clinical trials for the treatment of hemophilia A"],"prefix":"10.1080","volume":"31","author":[{"given":"Gianna M","family":"Guzzardo","sequence":"first","affiliation":[{"name":"Pediatric Hematology Oncology, Children\u2019s Hospital of Michigan, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Sidonio, Jr","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Oncology, Emory University and Aflac Cancer and Blood Disorders, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael U","family":"Callaghan","sequence":"additional","affiliation":[{"name":"Agios Pharmaceuticals, Cambridge, MA, USA"},{"name":"Department of Pediatrics, Central Michigan University School of Medicine, Mount Pleasant, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Regling","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Oncology, Children\u2019s Hospital of Michigan, Detroit, MI, USA"},{"name":"Department of Pediatrics, Central Michigan University School of Medicine, Mount Pleasant, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.2147\/PHMT.S293246"},{"key":"cit0003","first-page":"221","volume":"15","author":"Marchesini E","year":"2021","journal-title":"Biol targ ther"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2014.09.008"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04214.x"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001311"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00757.x"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457036"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056291"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.70"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-713289"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"cit0013","unstructured":"FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors. 2018."},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00017.x"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01474.x"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01075.x"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering5010007"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1177\/1076029614555902"},{"key":"cit0019","unstructured":"Study on the Dose-response relationship of pharmacodynamic parameters in patients with hemophilia with inhibitors. [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04789954?term=NCT04789954&draw=2&rank=1"},{"key":"cit0020","unstructured":"Prediction of the efficacy of activated recombinant human factor vii in adult congenital haemophilia A or B patients with inhibitors by use of thromboelastography. [cited 2022 Jun 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01561924?term=NCT01561924&draw=2&rank=1"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13428"},{"key":"cit0022","first-page":"1","volume":"2","author":"Calo D","year":"2015","journal-title":"Precis Med"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.3578.3578"},{"key":"cit0024","unstructured":"A study of a Long-Acting r-Factor 7a (Factor VIIa) in adult men with hemophilia A or B. [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02418793?term=NCT02418793&draw=2&rank=1"},{"key":"cit0025","unstructured":"A Single-dose, Dose-escalation study of a long-acting MOD-5014 in healthy adult male. [cited 2022 Jun 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02919800"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwt085"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1560259"},{"key":"cit0028","unstructured":"A Phase I Safety, Pharmacokinetics and pharmacodynamics study of recombinant factor VIIa in adult patients with hemophilia A or B (rhFVIIa). [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01708564?term=NCT01708564&draw=2&rank=1"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13357"},{"key":"cit0030","unstructured":"Phase 1 safety, pharmacokinetics and pharmacodynamics study of recombinant factor VIIa variant (813d) in adult subjects with hemophilia. [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01439971"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14247"},{"key":"cit0032","unstructured":"Study of coagulation factor viia variant marzeptacog alfa (Activated) in adult subjects with hemophilia A and B. [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03407651?term=NCT03407651&draw=2&rank=1"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12576"},{"key":"cit0034","unstructured":"Figueiredo M. Catalyst halts MarzAA program for hemophilia, despite positive results. Hemophilia News Today. 2021 [cited 2022 Jun 9]. Available from: Hemophilianewstoday.com\/2021\/11\/17\/catalyst-halts-marzaa-development-hemophilia-despite-positive-results"},{"key":"cit0035","unstructured":"Safety and mode of action of a single dose and multiple doses of long acting activated recombinant human factor VII in patients with haemophilia A and B. [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT00922792?term=NCT00922792&draw=2&rank=1"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13360"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S82457"},{"key":"cit0038","unstructured":"A Phase II, Muti-Center study of repeat dosing of PEG recombinant human coagulation factor VIII-Fc fusion protein for injection in subjects with severe Hemophilia A. [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05265286"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113575"},{"key":"cit0040","unstructured":"A Safety, Tolerability, and pharmacokinetics study of a single intravenous injection of recombinant coagulation factor VIII Fc - Von Willebrand factor - XTEN fusion protein. [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03205163"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002699"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.724864"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.199"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14755"},{"key":"cit0045","volume":"5","author":"Ay C","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279948"},{"key":"cit0047","unstructured":"BT200 in hereditary bleeding disorders. [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04677803"},{"key":"cit0048","volume":"5","author":"Ay C","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M507846200"},{"key":"cit0050","unstructured":"A safety study of STSP-0601 in adult patients with hemophilia A or B with inhibitor. [cited 2022 Jun 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04747964"},{"key":"cit0051","unstructured":"A safety and efficacy study of STSP-0601 in adult patients with Hemophilia A or B with inhibitor. [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05027230?term=nct05027230&draw=2&rank=1"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14186"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14403"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000083"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15397"},{"key":"cit0056","unstructured":"Extended half life factor (EHF) products for heavy menstrual bleeding in Hemophilia carriers. [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05281718?term=NCT05281718&draw=2&rank=1"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718635"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000364"},{"key":"cit0059","unstructured":"The safety and tolerability of serpinPC in healthy men and in men with severe blood disorders (Haemophilia A and B). [cited 2022 Jun 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04073498?term=nct04073498&draw=2&rank=1"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801662"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1650169"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1080\/10245330600574185"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-598268"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13304"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24777"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1027-y"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006315"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148040"},{"key":"cit0069","unstructured":"Emicizumab in acquired hemophilia A. [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04188639?term=NCT04188639&draw=2&rank=1"},{"key":"cit0070","unstructured":"Factor IX as Adjunctive Therapy to Emicizumab (EMIX). [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05281718?term=NCT05281718&draw=2&rank=1"},{"key":"cit0071","unstructured":"Hemlibra\u00ae (emicuzmab-kxwh) for US patients and caregivers. [cited 2022 Sept 8]. Available from: https:\/\/www.emicizumabinfo.com\/content\/dam\/gene\/emicizumabinfo\/pdf\/archived-reports\/reported-fatalities.pdf"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15187"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010331"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122817"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15682"},{"key":"cit0076","unstructured":"A research study of how a new medicine NNC0365-3769 (Mim8) works in the body of healthy people. [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05127473"},{"key":"cit0077","unstructured":"A research study investigating mim8 in people with Haemophilia A (FRONTIER1). [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04204408"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-10-0732"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3847"},{"key":"cit0080","unstructured":"An open-label extension study of an investigational drug, fitusiran, in patients with moderate or severe Hemophilia A or B. [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02554773"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15270"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1397.1397"},{"key":"cit0083","unstructured":"Alnylam Reports Patient Death in Fitusiran Clinical Study. National Hemophilia foundation. 2017 [cited 2022 Sept 8]. Available from: https:\/\/www.hemophilia.org\/news\/alnylam-reports-patient-death-in-fitusiran-clinical-study"},{"key":"cit0084","unstructured":"Update- FDA lifts suspension of Fitusiran trial. World Federation of Hemophilia. 2017 [cited 2022 Jun 2]. Available from: https:\/\/news.wfh.org\/update-fda-lifts-suspension-fitusiran-trial\/"},{"key":"cit0085","unstructured":"Taylor N. Sanofi plans 2021 restart for pediatric hemophilia trial hit by fallout from thrombotic events. Fierce Biotech. 2021 [cited 2022 Jun 2]. Available from: https:\/\/www.fiercebiotech.com\/biotech\/sanofi-plans-2021-restart-for-pediatric-hemophilia-trial-hit-by-fallout-from-thrombotic"},{"key":"cit0086","unstructured":"Fitusiran prophylaxis in male pediatric subjects Aged 1 to less than 12 years with Hemophilia A or B (ATLAS-PEDS). [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03974113"},{"key":"cit0087","unstructured":"Sanofi: data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors. ASH plenary and late-breaking session. 2021."},{"key":"cit0088","first-page":"67","volume":"48","author":"Kato H","year":"1996","journal-title":"Pol J Pharmacol"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.115.305996"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.59.061606.095605"},{"key":"cit0091","unstructured":"Safety of NNC 0172-0000-2021 in healthy male subjects and subjects with Haemophilia A or B (Explorer 1). [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01228669"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12864"},{"key":"cit0093","unstructured":"Trial Investigating Safety, Pharmacokinetics and pharmacodynamics of concizumab administered subcutaneously to haemophilia A subjects. [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02490787"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14272"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13627"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001542"},{"key":"cit0097","unstructured":"A trial evaluating the efficacy and safety of prophylactic administration of concizumab in Haemophilia A and B patients with inhibitors (explorerTM4). [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03196284"},{"key":"cit0098","unstructured":"A trial evaluating efficacy and safety of prophylactic administration of concizumab in patients with severe Haemophilia A without inhibitors (explorerTM5). [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03196297"},{"key":"cit0099","unstructured":"Ray F. Novo nordisk resumes Phase 3 trials of concizumab in Hemophilia A and B. Hemophilia News Today. 2020 [cited 2022 Jun 9]. Available from: hemophilianewstoday.com\/2020\/08\/14\/novo-nordisk-resumes-phase-3-trials-of-concizumab-in-hemophilia-a-and-b"},{"key":"cit0100","volume-title":"BAY 1093884 binds to the Kunitz 1 and 2 domain interface of tissue factor pathway inhibitor and inhibits its function","author":"Yegneswaran S","year":"2017"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0086-4"},{"key":"cit0102","unstructured":"A single escalating dose and multiple dose study of BAY 1093884 in subjects with severe Hemophilia Types A or B, with or without inhibitors. [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02571569"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114683"},{"key":"cit0104","unstructured":"A study to assess pharmacokinetics and pharmacodynamics following administration of BAY1093884 in patients with severe hemophilia. [cited 2022 Jun 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03481946?term=nct03481946&draw=2&rank=1"},{"issue":"5","key":"cit0105","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/hae.14595","volume":"28","author":"Mancuso ME","year":"2022","journal-title":"Haemophilia"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13820"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.03.010"},{"key":"cit0108","unstructured":"Dose escalation study of PF-06741086 in healthy subjects. [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02531815"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14207"},{"key":"cit0110","unstructured":"Study to evaluate safety and tolerability of a single dose of PF-06741086 in Chinese adult participants with severe hemophilia. [cited 2022 Jun 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04878731?term=nct04878731&draw=2&rank=1"},{"issue":"1","key":"cit0111","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/rth2.12159","volume":"3","author":"Mahlangu J","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"cit0112","unstructured":"PF-06741086 long-term treatment in severe Hemophilia. [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03363321"},{"key":"cit0113","unstructured":"PF-06741086 multiple dose study in severe hemophilia. [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02974855"},{"key":"cit0114","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12576","volume":"5","author":"Mahlangu J","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"cit0115","unstructured":"Open-Label extension study of marstacimab in Hemophilia participants with or without inhibitors. Open-Label extension study of marstacimab in Hemophilia participants with or without inhibitors. [cited 2022 Jun 2]."},{"key":"cit0116","unstructured":"Study of the efficacy and safety PF-06741086 in adult and teenage participants with severe Hemophilia A or moderately severe to severe hemophilia B. [cited 2022 Jun 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03938792?term=NCT03938792&draw=2&rank=1"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12438"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15244"},{"key":"cit0119","unstructured":"A study to investigate the safety, tolerability, PK and PD of MG1113 in healthy subjects and Hemophilia patients. [cited 2022 Jun 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03855696?term=nct03855696&draw=2&rank=1"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-011-0098-6"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.067124"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01839.x"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.12.038"},{"key":"cit0124","unstructured":"Rituximab to treat severe Hemophilia A (RICH). [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00331006"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-01-0078"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12586"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718791933"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706910"},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01001-08"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-462200"},{"key":"cit0131","unstructured":"Gene Therapy for Haemophilia A. (GO\u20138). [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03001830?term=nct03001830&draw=2&rank=1"},{"key":"cit0132","unstructured":"Study to test the safety and how well patients with severe Hemophilia A respond to treatment with BAY 2599023 (DTX 201). [cited 2022 Jun 7]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03588299"},{"key":"cit0133","unstructured":"ASC618 gene therapy in hemophilia A patients. [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04676048?term=nct04676048&draw=2&rank=1"},{"key":"cit0134","volume-title":"ASGCT 23rd Annual Meeting Abstract Presentation","author":"Veselinovic M","year":"2020"},{"key":"cit0135","unstructured":"A Gene Transfer Study for Hemophilia A. Previous study | return to list | next study A gene transfer study for Hemophilia A. [cited 2022 Jun 2]."},{"key":"cit0136","unstructured":"Dose-finding study of SPK-8016 gene therapy in patients with Hemophilia A to support evaluation in individuals with FVIII inhibitors. dose-finding study of SPK-8016 gene therapy in patients with Hemophilia A to support evaluation in individuals with FVIII inhibitors. [cited 2022 Jun 2]."},{"key":"cit0137","unstructured":"Spark Announces Preliminary Data from Investigational Gene Therapy Trial. National Hemophilia Foundation. 2021. [cited 2022 Aug 2]. Available from: https:\/\/www.hemophilia.org\/news\/spark-announces-preliminary-data-from-investigational-gene-therapy-trial"},{"key":"cit0138","unstructured":"A study of BAX 888 in male adults with severe Hemophilia A. [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03370172?term=NCT03370172&draw=2&rank=1"},{"key":"cit0139","unstructured":"Gene therapy study in severe Haemophilia A patients (270-201). [cited 2022 Jun 7]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02576795"},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.008"},{"key":"cit0141","unstructured":"Safety, tolerability, and efficacy study of valoctocogene roxaparvovec in Hemophilia A with active or prior inhibitors. [cited 2022 Jun 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04684940?term=Valoctocogene+roxaparvovec&draw=2&rank=3"},{"key":"cit0142","unstructured":"Gene therapy study in severe Hemophilia A patients with antibodies against AAV5 (27\u2013203). [cited 2022 Jun 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03520712?term=Valoctocogene+roxaparvovec&draw=2&rank=5"},{"key":"cit0143","unstructured":"A study of recombinant AAV2:6 human factor 8 gene therapy SB-525 (PF-07055480) in subjects with severe Hemophilia A. [cited 2022 Jun 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03061201?term=SB-525+%28PF-07055480%29&draw=2&rank=1"},{"key":"cit0144","unstructured":"Hematopoietic stem cell transplantation gene therapy for treatment of severe Hemophilia A (NCT05265767). [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05265767?term=NCT05265767&draw=2&rank=1"},{"key":"cit0145","unstructured":"Hematopoietic stem cell transplantation gene therapy for treatment of severe Hemophilia A (NCT04418414). [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04418414?term=nct04418414&draw=2&rank=1"},{"key":"cit0146","unstructured":"Lentiviral FVIII Gene Therapy. [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03217032?term=nct03217032&draw=2&rank=1"},{"key":"cit0147","unstructured":"Gene therapy trial for platelet derived factor VIII production in Hemophilia A. [cited 2022 Jun 2]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03818763?term=nct03818763&draw=2&rank=1"},{"key":"cit0148","first-page":"1","volume":"1","author":"Nathwani AC","year":"2019","journal-title":"Hematol Am SocHematol Educ Progr"},{"key":"cit0149","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2019.08.012"},{"key":"cit0150","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"cit0151","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14485"},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211032452"},{"key":"cit0153","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13819"},{"key":"cit0154","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1875817"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2022.2138742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T16:53:36Z","timestamp":1671814416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2022.2138742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":154,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,2]]}},"alternative-id":["10.1080\/13543784.2022.2138742"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2022.2138742","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-07-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}